International Edition
Latest News
Health

UAL Develops Structured Fats from Echium Oil That Reduce Liver Fat and Weight Gain in Mice

University of Almería scientists have engineered two novel structured fats from Echium plantagineum seed oil that curbed weight gain, liver fat and blood lipids in mice fed a high‑fat diet, according to peer‑reviewed studies published in Food &…

UAL Develops Structured Fats from Echium Oil That Reduce Liver Fat and Weight Gain in Mice

University of Almería scientists have engineered two novel structured fats from Echium plantagineum seed oil that curbed weight gain, liver fat and blood lipids in mice fed a high‑fat diet, according to peer‑reviewed studies published in Food & Function and Foods.

The first ingredient, a 1,3‑diacylglycerol enriched with gamma‑linolenic acid (GLA) and stearidonic acid (SDA), limited weight gain and cut hepatic steatosis, plasma cholesterol and triglycerides in the animal model. The second, a lysophosphatidylcholine (LPC) made through a solvent‑free enzymatic route, displayed high oxidative stability — a prerequisite for functional foods and supplements.

The work was led by Miguel Ángel Rincón‑Cervera of the UAL’s group Química de biomoléculas y procesos alimentarios (FQM‑364) with collaborators at the Instituto de Nutrición y Tecnología de los Alimentos and the Facultad de Medicina at Universidad de Chile, as well as the Facultad de Medicina y Salud at Universidad Finis Terrae, according to Novaciencia.

Rare fatty acids, new architecture

Echium plantagineum — viper’s bugloss or Paterson’s curse — yields seed oil that naturally contains both GLA, an omega‑6, and SDA, an omega‑3 precursor to EPA. Both are scarce in mainstream dietary oils and oxidise rapidly, limiting their use in food products.

To bypass those hurdles, the team used enzymatic interesterification, a process that rearranges fatty acids on a glycerol backbone without organic solvents, to create two novel structured lipids.

1,3‑DAG blunts metabolic damage in mice

The Food & Function study (2026) tested 1,3‑DAGs enriched with GLA and SDA in mice with diet‑induced obesity. Animals receiving the structured fat gained less weight than controls despite identical calorie intake. They also showed reduced hepatic steatosis, lower plasma total cholesterol and triglycerides, and decreased markers of inflammation and oxidative stress.

“These results suggest that the positional distribution of fatty acids on the glycerol backbone influences how the body metabolises dietary fat,” the research team said in the paper.

LPC carrier resists oxidation

The Foods study (2026) focused on lysophosphatidylcholine carrying the same fatty acids. The solvent‑free enzymatic synthesis yielded an LPC with strong resistance to oxidation, making it a stable carrier for incorporating GLA and SDA into food matrices or nutraceuticals. LPC’s amphiphilic structure may also enhance intestinal absorption of the target fatty acids.

From bench to application

Both publications frame the ingredients as platforms for next‑generation functional foods. The oxidative stability of the LPC formulation addresses a key industry bottleneck: the rapid degradation of polyunsaturated oils during processing and shelf life. The 1,3‑DAG structure, already recognised in some markets for reducing post‑prandial triglyceride response, gains a new nutritional profile through the incorporation of GLA and SDA.

The researchers caution that the metabolic benefits have only been demonstrated in a pre‑clinical rodent model. Human trials will be required to confirm safety, bioavailability and effective dosage before any health claims can be substantiated.

Echium oil uniqueness and 1,3-DAG structure explained

What is Echium plantagineum and why is its oil unique?
Echium plantagineum (viper’s bugloss) is a wild plant whose seeds yield oil containing both gamma‑linolenic acid (an omega‑6) and stearidonic acid (an omega‑3). Most common vegetable oils lack one or both of these fatty acids.

How do 1,3‑diacylglycerols differ from conventional triglycerides?
In conventional triglycerides, fatty acids occupy all three positions on the glycerol backbone. In 1,3‑DAGs, the middle (sn‑2) position is free, which alters digestion and absorption pathways and can reduce post‑meal triglyceride spikes.

Are these ingredients approved for human consumption?
Not yet. The published studies are pre‑clinical (mouse model). Regulatory approval and human clinical trials are needed before they can be used in foods or supplements.

What is the advantage of a solvent‑free enzymatic process?
It avoids residual organic solvents in the final product, aligns with clean‑label trends, and allows precise positional control of fatty acids on the lipid backbone.

About the author: Health Desk

Health Desk at Archynewsy.